Heron Therapeutics appoints Christian Waage to its Board of Directors

– USA, CA –  Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, announced the appointment of Christian Waage to Heron’s Board of Directors.

“Christian’s leadership experience in the biotechnology and healthcare industry along with his transaction experience and specialized regulatory, legal, and financial knowledge will be invaluable to Heron,” said CEO, Dr. Barry Quart. “We are thrilled to have Christian join the Heron team, particularly at such a transformative time for the Company.”

About Christian Waage

Christian Waage currently serves as Managing Director at Receptos, a wholly-owned subsidiary of Celgene Corporation. Mr. Waage joined Receptos in December 2013 as SVP and General Counsel and played an instrumental role in its acquisition by Celgene for $7.2B in August 2015. Before Receptos, he served as VP, General Counsel, and Corporate Secretary at Websense, Inc. from July 2012 until its acquisition by Vista Equity Partners for $1B in August 2013. In addition to overseeing its acquisition, his responsibilities at Websense included all legal affairs, including SEC reporting and compliance, corporate governance, litigation, and licensing operations. Before Websense, Mr. Waage served as VP, General Counsel, Before and Corporate Secretary of Ardea Biosciences, Inc. from March 2008 until its acquisition by AstraZeneca PLC for $1.3B in July 2012. Before Ardea Biosciences, Mr. Waage practiced law for over a decade at DLA Piper, where he was a partner.

Mr. Waage received a J.D. from the University of San Diego School of Law and a B.A. degree in Economics from the University of California, San Diego.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a biotechnology company focused on improving patients’ livesBefore by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. Heron’s goal is to build on therapeutics with well-known pharmacology by improving their tolerability and efficacy as well as broadening their potential field of use.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here the original post =>